Below are the most recent publications written about "Biphenyl Compounds" by people in Profiles.
-
Nathaniel S, McGinty S, Witman MA, Edwards DG, Farquhar WB, Hosmane V, Wenner MM. A new lead: Sacubitril-valsartan's unique benefit in HFrEF could lie with sympathoinhibition. Auton Neurosci. 2022 03; 238:102949.
-
Kim DH, Chien FJ, Eisen HJ. Pharmacologic Management for Heart Failure and Emerging Therapies. Curr Cardiol Rep. 2017 08 24; 19(10):94.
-
Owens EA, Jie L, Reyes BAS, Van Bockstaele EJ, Osei-Owusu P. Elastin insufficiency causes hypertension, structural?defects and abnormal remodeling?of?renal vascular signaling. Kidney Int. 2017 11; 92(5):1100-1118.
-
Patsenker E, Chicca A, Petrucci V, Moghadamrad S, de Gottardi A, Hampe J, Gertsch J, Semmo N, Stickel F. 4-O'-methylhonokiol protects from alcohol/carbon tetrachloride-induced liver injury in mice. J Mol Med (Berl). 2017 10; 95(10):1077-1089.
-
Acharya NK, Qi X, Goldwaser EL, Godsey GA, Wu H, Kosciuk MC, Freeman TA, Macphee CH, Wilensky RL, Venkataraman V, Nagele RG. Retinal pathology is associated with increased blood-retina barrier permeability in a diabetic and hypercholesterolaemic pig model: Beneficial effects of the LpPLA2 inhibitor Darapladib. Diab Vasc Dis Res. 2017 05; 14(3):200-213.
-
Doshi KA, Trotta R, Natarajan K, Rassool FV, Tron AE, Huszar D, Perrotti D, Baer MR. Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress. Oncotarget. 2016 Jul 26; 7(30):48280-48295.
-
Feldman AM, Haller JA, DeKosky ST. Valsartan/Sacubitril for Heart Failure: Reconciling Disparities Between Preclinical and Clinical Investigations. JAMA. 2016 Jan 05; 315(1):25-6.
-
Schultz TC, Valenzano JP, Verzella JL, Umland EM. Odanacatib: an emerging novel treatment alternative for postmenopausal osteoporosis. Womens Health (Lond). 2015 Nov; 11(6):805-14.
-
Acharya NK, Levin EC, Clifford PM, Han M, Tourtellotte R, Chamberlain D, Pollaro M, Coretti NJ, Kosciuk MC, Nagele EP, Demarshall C, Freeman T, Shi Y, Guan C, Macphee CH, Wilensky RL, Nagele RG. Diabetes and hypercholesterolemia increase blood-brain barrier permeability and brain amyloid deposition: beneficial effects of the LpPLA2 inhibitor darapladib. J Alzheimers Dis. 2013; 35(1):179-98.
-
Nagano JM, Hsu KL, Whitby LR, Niphakis MJ, Speers AE, Brown SJ, Spicer T, Fernandez-Vega V, Ferguson J, Hodder P, Srinivasan P, Gonzalez TD, Rosen H, Bahnson BJ, Cravatt BF. Selective inhibitors and tailored activity probes for lipoprotein-associated phospholipase A(2). Bioorg Med Chem Lett. 2013 Feb 01; 23(3):839-43.